Zoetis Inc. (NYSE:ZTS) Shares Acquired by Peddock Capital Advisors LLC

Peddock Capital Advisors LLC grew its stake in Zoetis Inc. (NYSE:ZTS) by 3.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,455 shares of the company’s stock after purchasing an additional 275 shares during the period. Peddock Capital Advisors LLC’s holdings in Zoetis were worth $1,456,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Asset Dedication LLC raised its stake in shares of Zoetis by 4.8% during the second quarter. Asset Dedication LLC now owns 1,174 shares of the company’s stock valued at $204,000 after purchasing an additional 54 shares during the period. Forza Wealth Management LLC raised its stake in shares of Zoetis by 1.8% during the second quarter. Forza Wealth Management LLC now owns 3,313 shares of the company’s stock valued at $574,000 after purchasing an additional 58 shares during the period. L. Roy Papp & Associates LLP raised its stake in shares of Zoetis by 2.8% during the second quarter. L. Roy Papp & Associates LLP now owns 2,221 shares of the company’s stock valued at $385,000 after purchasing an additional 60 shares during the period. Angeles Wealth Management LLC raised its stake in shares of Zoetis by 3.8% during the first quarter. Angeles Wealth Management LLC now owns 1,702 shares of the company’s stock valued at $288,000 after purchasing an additional 62 shares during the period. Finally, Edge Capital Group LLC raised its stake in shares of Zoetis by 3.7% during the second quarter. Edge Capital Group LLC now owns 1,786 shares of the company’s stock valued at $310,000 after purchasing an additional 64 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on ZTS. Stifel Nicolaus lifted their price objective on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Piper Sandler lifted their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Finally, BTIG Research lifted their price target on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and a consensus price target of $220.38.

Zoetis Stock Performance

ZTS stock traded up $0.63 during trading on Wednesday, hitting $188.00. 115,317 shares of the company’s stock traded hands, compared to its average volume of 2,557,194. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The stock has a fifty day moving average price of $187.52 and a two-hundred day moving average price of $175.77. The stock has a market capitalization of $85.17 billion, a price-to-earnings ratio of 36.10, a price-to-earnings-growth ratio of 2.91 and a beta of 0.89.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The company had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. During the same quarter in the previous year, the company posted $1.41 earnings per share. The company’s revenue for the quarter was up 8.3% compared to the same quarter last year. As a group, equities analysts anticipate that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.